|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||97.29 - 97.61|
|52-week range||97.29 - 97.61|
|Beta (5Y monthly)||0.70|
|PE ratio (TTM)||21.42|
|Earnings date||02 Feb 2022 - 07 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
With me as usual are Kevin Gorman, our chief executive officer; Matt Abernethy, our chief financial officer; Eiry Roberts, our chief medical officer; Eric Benevich, our chief commercial officer; and Kyle Gano, our chief business development and strategy officer. Before we get going, I'll remind everyone that during today's call, we will be making forward-looking statements.
Neurocrine (NBIX) delivered earnings and revenue surprises of -57.58% and 1.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...